AR103680A1 - Inhibidores selectivos de bace1 - Google Patents
Inhibidores selectivos de bace1Info
- Publication number
- AR103680A1 AR103680A1 ARP160100396A ARP160100396A AR103680A1 AR 103680 A1 AR103680 A1 AR 103680A1 AR P160100396 A ARP160100396 A AR P160100396A AR P160100396 A ARP160100396 A AR P160100396A AR 103680 A1 AR103680 A1 AR 103680A1
- Authority
- AR
- Argentina
- Prior art keywords
- bace1
- selective inhibitors
- compound
- pharmaceutical use
- salt acceptable
- Prior art date
Links
- 102100021257 Beta-secretase 1 Human genes 0.000 title 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente solicitud proporciona un compuesto o una sal aceptable para uso farmacéutico en el tratamiento del Alzheimer. Reivindicación 1: Un compuesto de la fórmula (1) en donde R es metilo, etilo, o ciclopropilo; o una sal aceptable para uso farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119391P | 2015-02-23 | 2015-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103680A1 true AR103680A1 (es) | 2017-05-24 |
Family
ID=55442893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100396A AR103680A1 (es) | 2015-02-23 | 2016-02-12 | Inhibidores selectivos de bace1 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9522923B2 (es) |
| EP (1) | EP3262051B1 (es) |
| JP (1) | JP6111001B1 (es) |
| KR (1) | KR101945139B1 (es) |
| CN (1) | CN107257801B (es) |
| AR (1) | AR103680A1 (es) |
| AU (1) | AU2016223072B2 (es) |
| BR (1) | BR112017013936A2 (es) |
| CA (1) | CA2972098A1 (es) |
| CL (1) | CL2017002090A1 (es) |
| CO (1) | CO2017008382A2 (es) |
| CR (1) | CR20170315A (es) |
| DO (1) | DOP2017000178A (es) |
| EA (1) | EA031546B1 (es) |
| EC (1) | ECSP17054980A (es) |
| GT (1) | GT201700185A (es) |
| IL (1) | IL252969A0 (es) |
| MX (1) | MX367940B (es) |
| NZ (1) | NZ732940A (es) |
| PE (1) | PE20171337A1 (es) |
| PH (1) | PH12017501523A1 (es) |
| SG (1) | SG11201705764SA (es) |
| SI (1) | SI3262051T1 (es) |
| TN (1) | TN2017000355A1 (es) |
| TW (1) | TWI627177B (es) |
| WO (1) | WO2016137788A1 (es) |
| ZA (1) | ZA201704293B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| CA2977667C (en) | 2015-03-19 | 2019-08-20 | Eli Lilly And Company | Aminothiazine compounds useful as selective bace1 inhibitors |
| AR104241A1 (es) | 2015-04-29 | 2017-07-05 | Lilly Co Eli | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| SG11201808270PA (en) | 2016-03-31 | 2018-10-30 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| BR112018068676A2 (pt) | 2016-03-31 | 2019-01-15 | Janssen Pharmaceuticals Inc | derivados de indol substituídos como inibidores da replicação viral do dengue |
| MA44502A (fr) | 2016-04-01 | 2019-02-06 | Janssen Pharmaceuticals Inc | Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| US20190365774A1 (en) * | 2016-08-18 | 2019-12-05 | Eli Lilly And Company | Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| TWI771420B (zh) | 2017-05-22 | 2022-07-21 | 美商健生醫藥公司 | 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物（一） |
| US11407715B2 (en) | 2017-05-22 | 2022-08-09 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080029965A (ko) | 2005-06-14 | 2008-04-03 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제 |
| JP4520533B2 (ja) * | 2008-01-18 | 2010-08-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 縮合アミノジヒドロチアジン誘導体 |
| US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| NZ591878A (en) | 2008-09-30 | 2012-06-29 | Eisai R&D Man Co Ltd | Novel fused aminodihydrothiazine derivative |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| JP5554346B2 (ja) | 2009-12-09 | 2014-07-23 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
| JPWO2011071109A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | アミノ基を有する縮合ヘテロ環化合物 |
| GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101140D0 (en) * | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101139D0 (en) * | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| AR086539A1 (es) | 2011-05-24 | 2014-01-08 | Bristol Myers Squibb Co | COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE |
| WO2014015125A1 (en) | 2012-07-19 | 2014-01-23 | Eisai R&D Management Co., Ltd. | Fused aminodihydrothiazine derivative salts and uses thereof |
| GB201212816D0 (en) * | 2012-07-19 | 2012-09-05 | Eisai Ltd | Novel compounds |
| TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
| TWI639607B (zh) * | 2013-06-18 | 2018-11-01 | 美國禮來大藥廠 | Ｂａｃｅ抑制劑 |
| AR104241A1 (es) * | 2015-04-29 | 2017-07-05 | Lilly Co Eli | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos |
-
2016
- 2016-02-12 AR ARP160100396A patent/AR103680A1/es unknown
- 2016-02-15 TW TW105104352A patent/TWI627177B/zh not_active IP Right Cessation
- 2016-02-17 JP JP2016558188A patent/JP6111001B1/ja not_active Expired - Fee Related
- 2016-02-17 WO PCT/US2016/018160 patent/WO2016137788A1/en not_active Ceased
- 2016-02-17 EA EA201791684A patent/EA031546B1/ru not_active IP Right Cessation
- 2016-02-17 SI SI201630428T patent/SI3262051T1/sl unknown
- 2016-02-17 CN CN201680011583.5A patent/CN107257801B/zh not_active Expired - Fee Related
- 2016-02-17 AU AU2016223072A patent/AU2016223072B2/en not_active Ceased
- 2016-02-17 EP EP16706731.3A patent/EP3262051B1/en active Active
- 2016-02-17 KR KR1020177023007A patent/KR101945139B1/ko not_active Expired - Fee Related
- 2016-02-17 MX MX2017010861A patent/MX367940B/es active IP Right Grant
- 2016-02-17 CA CA2972098A patent/CA2972098A1/en not_active Abandoned
- 2016-02-17 TN TNP/2017/000355A patent/TN2017000355A1/en unknown
- 2016-02-17 PE PE2017001256A patent/PE20171337A1/es unknown
- 2016-02-17 SG SG11201705764SA patent/SG11201705764SA/en unknown
- 2016-02-17 NZ NZ732940A patent/NZ732940A/en not_active IP Right Cessation
- 2016-02-17 CR CR20170315A patent/CR20170315A/es unknown
- 2016-02-17 US US15/045,305 patent/US9522923B2/en not_active Expired - Fee Related
- 2016-02-17 BR BR112017013936A patent/BR112017013936A2/pt not_active Application Discontinuation
-
2017
- 2017-06-18 IL IL252969A patent/IL252969A0/en unknown
- 2017-06-23 ZA ZA2017/04293A patent/ZA201704293B/en unknown
- 2017-07-31 DO DO2017000178A patent/DOP2017000178A/es unknown
- 2017-08-01 GT GT201700185A patent/GT201700185A/es unknown
- 2017-08-16 CO CONC2017/0008382A patent/CO2017008382A2/es unknown
- 2017-08-16 CL CL2017002090A patent/CL2017002090A1/es unknown
- 2017-08-22 EC ECIEPI201754980A patent/ECSP17054980A/es unknown
- 2017-08-23 PH PH12017501523A patent/PH12017501523A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| MX380394B (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| TW201613872A (en) | IRAK4 inhibiting agents | |
| MX2017009449A (es) | Inhibidor jak. | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| MX2017006224A (es) | Derivados heterociclicos y usos de los mismos. | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| SV2016005351A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| NI201800071A (es) | Compuestos de isoindol | |
| SV2016005313A (es) | Derivados de carboxamida | |
| BR112017000730B8 (pt) | Derivados de pirrolidinona como inibidores de metap-2, e medicamentos | |
| MX390051B (es) | Antagonistas de ep4. | |
| JOP20190049A1 (ar) | مثبطات دوبامين-b-هيدروكسيلاز | |
| UY36123A (es) | Derivados de carboxamida | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| MX2017006110A (es) | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| EA201501130A1 (ru) | Офтальмологическая фармацевтическая композиция |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |